Wilson Sonsini Goodrich & Rosati advised Invus, F-Prime, and MedTech Venture Partners on the transaction. Zenflow, Inc., a medical device company developing a minimally invasive treatment...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Cellino Biotech, Inc. on the transaction. Cellino Biotech, Inc. (Cellino) announced that the Advanced Research Projects Agency for Health (ARPA-H),...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction. LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, announced that it has entered into...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal. Oricell Therapeutics Co., Ltd, a China-based innovative pharmaceutical company committed to the development of tumor...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised a16z on the deal. Pearl Health, a leading technology company focused on physician enablement and risk bearing in value-based care, announced it has...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion...
You must be a Standard 1 Year member to access this content.
